Show simple item record

AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.

dc.contributor.authorLillian, S
dc.contributor.authorDe Bono, J
dc.contributor.authorHigano, C
dc.contributor.authorShapiro, G
dc.contributor.authorBrugger, W
dc.contributor.authorMitchell, P
dc.contributor.authorColebrook, S
dc.contributor.authorKlinowska, T
dc.contributor.authorBarry, S
dc.contributor.authorDean, Emma J
dc.contributor.authorMartin-Mills, J
dc.contributor.authorWisinski, K
dc.contributor.authorMoorthy, G
dc.contributor.authorMills, J
dc.contributor.authorCruzalegui, F
dc.contributor.authorTolaney, S
dc.contributor.authorLang, J
dc.contributor.authorJose De Miquel Luken, M
dc.contributor.authorKunar, R
dc.contributor.authorChatta, G
dc.date.accessioned2017-03-30T17:47:53Z
dc.date.available2017-03-30T17:47:53Z
dc.date.issued2016-12
dc.identifier.citationAZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate. 2016, 69 (Suppl 1):S19 European Journal of Canceren
dc.identifier.issn09598049
dc.identifier.doi10.1016/S0959-8049(16)32637-5
dc.identifier.urihttp://hdl.handle.net/10541/620224
dc.language.isoenen
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0959804916326375en
dc.rightsArchived with thanks to European Journal of Canceren
dc.titleAZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentPrincess Margaret Hospital, Oncology, Toronto, Canadaen
dc.identifier.journalEuropean Journal of Canceren


Files in this item

This item appears in the following Collection(s)

Show simple item record